Surrogates for Fracture Endpoints in Clinical Trials

This publication has 17 references indexed in Scilit:

• Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone Density
  Journal of Clinical Endocrinology & Metabolism, 2000
• Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical Trial
  JAMA, 1999
• Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis
  Arthritis & Rheumatism, 1999
• Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women
  New England Journal of Medicine, 1997
• Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
  BMJ, 1996
• The worldwide problem of osteoporosis: Insights afforded by epidemiology
  Bone, 1995
• Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. A one-year study.
  Journal of Clinical Investigation, 1995
• Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen
  Annals of Internal Medicine, 1992
• A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis
  Osteoporosis International, 1991
• Effect of Fluoride Treatment on the Fracture Rate in Postmenopausal Women with Osteoporosis
  New England Journal of Medicine, 1990